Evidence map›Paper›PMID 30626830›Full record

ArticleInternal medicine (Tokyo, Japan)2019

Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy.

Naoko Katsurada, Motoko Tachihara, Naoe Jimbo, Kiyoko Koyama, Kyosuke Nakata, Tatsuya Nagano, Masatsugu Yamamoto, Hiroshi Kamiryo, Kazuyuki Kobayashi, Yoshihiro Nishimura

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Naoko KatsuradaDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Motoko TachiharaDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Naoe JimboDepartment of Diagnostic Pathology, Kobe University Graduate School of Medicine, Japan.
Kiyoko KoyamaDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Kyosuke NakataDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Tatsuya NaganoDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Masatsugu YamamotoDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Hiroshi KamiryoDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Kazuyuki KobayashiDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Yoshihiro NishimuraDivision of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
Kobe University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertrophic pulmonary osteoarthropathy (HPO) is a paraneoplastic syndrome characterized by digital clubbing, arthritis, and periostitis. Tumor removal usually leads to the resolution of these symptoms. We herein report the efficacy of crizotinib treatment for treating the symptoms of HPO associated with c-ros oncogene 1 receptor tyrosine kinase (ROS1)-rearranged lung cancer. A 71-year-old woman presented with a pulmonary tumor and arthritis. She was diagnosed with a ROS1-rearranged lung adenocarcinoma [stage IIIB (cT4N2M0) ] with HPO. Crizotinib dramatically reduced the tumor size and resolved the symptoms. After two months of crizotinib treatment, she underwent lobectomy, and a pathological evaluation revealed ypstage IIIA (ypT3a, ypN1). Crizotinib treatment was effective for reducing the tumor size and improving the symptoms of HPO.

Indexed as

Adenocarcinoma of LungAgedAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCrizotinibFemaleHumansOsteoarthropathy, Secondary HypertrophicProtein-Tyrosine KinasesProto-Oncogene ProteinsTreatment OutcomeAntineoplastic AgentsCrizotinibProtein-Tyrosine KinasesProto-Oncogene ProteinsROS1 protein, humancrizotinibhypertrophic pulmonary osteoarthropathyparaneoplastic syndromeROS1-rearranged lung cancer

Identifiers

PMID30626830
PMCPMC6548934
OpenAlexW2910872696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.